tradingkey.logo

Briacell’S Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® And Control Group In Metastatic Breast Cancer

ReutersJul 11, 2025 11:33 AM

- Briacell Therapeutics Corp BCT.TO:

  • BRIACELL’S BRIA-IMT™ DEMONSTRATES SURVIVAL ADVANTAGE OVER TRODELVY® AND CONTROL GROUP IN METASTATIC BREAST CANCER

  • BRIACELL THERAPEUTICS CORP - NO TREATMENT-RELATED DISCONTINUATIONS REPORTED FOR BRIACELL'S BRIA-IMT

  • BRIACELL THERAPEUTICS CORP - ANNOUNCES UPDATED PHASE 2 DATA FOR BRIA-IMT

  • BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 13.9 MONTHS OS IN TNBC

  • BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 17.3 MONTHS OS IN HR+ BREAST CANCER

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI